Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments
Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments
复制标题
DOI：
10.1016/j.cellimm.2021.104301
复制
发表时间：
2021-02-12
影响因子：
4.3
通讯作者：
Colombo, Mario P.
中科院分区：
文献类型：
--
作者：
Jachetti, Elena;Sangaletti, Sabina;Colombo, Mario P.
靶向PD-1/PD-L1轴的免疫检查点阻断（ICB）是治疗多种癌症的主要突破。然而，并非所有患者都受益于这种治疗，临床反应并不总是与肿瘤细胞的PD-L1表达相关。肿瘤微环境，包括髓源性抑制细胞（MDSC），可以影响对ICB的治疗抗性。MDSC还表达PD-L1，这有助于其抑制活性。此外，包括化疗、放疗、放疗和靶向治疗在内的抗癌疗法可以调节MDSC的募集、活性和PD-L1表达。这种效应也可以通过针对代谢和生活方式的创新抗癌治疗来诱导。癌症进展的结果可以是阳性或阴性，这取决于肿瘤类型、治疗方案和可能与ICB联合使用。需要进一步的研究来更好地了解癌症治疗对PD 1/PD-L1轴的影响，以确定哪些患者可以从包括ICB在内的组合方案中受益，或者应该避免它。
Immuno checkpoint blockade (ICB) targeting the PD-1/PD-L1 axis is the main breakthrough for the treatment of several cancers. Nevertheless, not all patients benefit from this treatment and clinical response not always correlates with PD-L1 expression by tumor cells. The tumor microenvironment, including myeloid derived suppressor cells (MDSCs), can influence therapeutic resistance to ICB. MDSCs also express PD-L1, which contributes to their suppressive activity. Moreover, anticancer therapies including chemotherapy, radiotherapy, hormone-and targeted-therapies can modulate MDSCs recruitment, activity and PD-L1 expression. Such effects can be induced also by innovative anticancer treatments targeting metabolism and lifestyle. The outcome on cancer progression can be either positive or negative, depending on tumor type, treatment schedule and possible combination with ICB. Further studies are needed to better understand the effects of cancer therapies on the PD1/PD-L1 axis, to identify patients that could benefit from combinatorial regimens including ICB or that rather should avoid it.